Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03196297 · ClinicalTrials.gov registry record · Phase 2
A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors
A Phase 2 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT03196297 is a Phase 2 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 36 participants.
The verdict
NCT03196297, a Phase 2 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
This trial is conducted in Asia, Europe and the United States of America (USA). The aim of the trial is to assess the efficacy of concizumab administered s.c. (subcutaneously, under the skin) once daily in preventing bleeding episodes in patients with severe haemophilia A without inhibitors.
Interventions
- DRUG Concizumab
- DRUG Turoctocog alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2017-08-16 |
| Est. Completion | 2020-06-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03196297
The ClinicalTrials.gov registry entry for NCT03196297 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Concizumab is the first listed.
NCT03196297 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03196297 about?
NCT03196297 is a clinical study titled "A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors". This trial is conducted in Asia, Europe and the United States of America (USA). The aim of the trial is to assess the efficacy of concizumab administered s.c. (subcutaneously, under the skin) once daily in preventing bleeding episodes in patients with severe haemophilia A without inhibitors.
What is the current status of trial NCT03196297?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2017-08-16. Estimated completion is 2020-06-03.
What interventions are being tested in trial NCT03196297?
The interventions under investigation include: Concizumab (DRUG), Turoctocog alfa (DRUG).
Who is sponsoring clinical trial NCT03196297?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.